drugset / Trial / NCT06084689
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.
Timeline
- Start
- 2024-06-14
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
Outcome
Outcome not reported
Stopped: “Discontinuation of molecule development”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigimadlin | Small molecule | — | — |
| Subject | Ezabenlimab | Monoclonal antibody | — | — |